| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAET1L |
| Uniprot No | Q5VY80 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-218 aa |
| 活性数据 | RRDDP HSLCYDITVI PKFRPGPRWC AVQGQVDEKT FLHYDCGNKT VTPVSPLGKK LNVTMAWKAQ NPVLREVVDI LTEQLLDIQL ENYTPKEPLT LQARMSCEQK AEGHSSGSWQ FSIDGQTFLL FDSEKRMWTT VHPGARKMKE KWENDKDVAM SFHYISMGDC IGWLEDFLMG MDSTLEPSAG APLAMSSG |
| 分子量 | 27.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人RAET1L蛋白的3篇示例参考文献(虚构示例，仅作参考)：
---
1. **文献名称**: "RAET1L: A novel ligand for NKG2D involved in human cytotoxic cell activation"
**作者**: Smith A, Jones B. et al.
**摘要**: 本研究鉴定了RAET1L作为NKG2D受体的新型配体，证明其重组蛋白可在体外显著增强NK细胞的细胞毒性活性。研究揭示了RAET1L在肿瘤细胞应激时的表达上调及其免疫调控作用。
2. **文献名称**: "Recombinant expression and functional characterization of RAET1L in modulating T-cell responses"
**作者**: Chen L, Wang Y.
**摘要**: 作者通过哺乳动物表达系统成功纯化了重组RAET1L蛋白，并发现其通过结合NKG2D激活CD8+ T细胞，为感染性疾病中的T细胞免疫应答机制提供了新见解。
3. **文献名称**: "Structural insights into RAET1L protein and its interaction with NKG2D receptor"
**作者**: Lee S, Kim H. et al.
**摘要**: 本研究解析了重组RAET1L蛋白的晶体结构，揭示了其与NKG2D受体结合的关键结构域，为开发基于RAET1L的免疫治疗策略奠定基础。
---
注：以上文献信息为假设案例，实际研究中请通过 **PubMed/Google Scholar** 检索真实文献。RAET1L相关研究可围绕其在NKG2D通路、肿瘤免疫及重组蛋白应用等领域展开。
RAET1L (Retinoic Acid Early Transcript 1L), also known as ULBP5. is a human protein belonging to the UL16-binding protein (ULBP) family, which comprises ligands for the activating receptor NKG2D expressed on natural killer (NK) cells and subsets of T cells. Structurally, RAET1L is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein with conserved α1/α2 domains resembling MHC class I molecules, though it lacks antigen-presenting functionality. Its expression is often induced under stress conditions, such as viral infection, DNA damage, or malignant transformation, serving as a "danger signal" to recruit immune effector cells.
The interaction between RAET1L and NKG2D triggers cytotoxic responses, enhancing immune surveillance against infected or transformed cells. Studies suggest its dysregulation in cancers, with tumor cells overexpressing RAET1L to either evade immune detection or succumb to NK cell-mediated elimination, depending on context. Recombinant RAET1L protein is commonly produced in mammalian or bacterial systems for functional studies, antibody development, or therapeutic exploration. Its role in modulating innate and adaptive immunity has spurred interest in cancer immunotherapy strategies, including NKG2D-targeted therapies. However, its precise mechanistic contributions and therapeutic potential remain under investigation, particularly in balancing pro-inflammatory effects and immune tolerance.
×
